The rare disease drug market is making history with its steady growth and burgeoning pipeline—and owing to continuing breakthroughs in gene therapy, the biggest advances are yet to come. Rebecca Mayer Knutsen reports on a sector that is thriving—and on the possibility that issues around pricing can slow its surge
Session: Inter-generational CEO Summit Panel
Session: Inter-generational CEO Summit Panel
Session: Inter-generational CEO Summit Panel
Session: Navigating Pharma Internal
Session: Rapid innovation and Big Pharma
Thomas Sack, President and CEO, MRIGlobal
Click the above link to access the complete Digital Edition of the January 2015 issue of MM&M, with all text, charts and pictures.
Change within a set-in-its-ways industry can be scary—that is, unless you've got the will and bravado to tackle it head-on. Here are the 40 inventors, strategists, advocates and wonks who are challenging, disrupting and otherwise transforming the healthcare business.
At any well-run business meeting, a smartphone is not only disruptive but also signals that its user is less than fully engaged with the business at hand
We need to help our health systems and healthcare companies function like agile start-ups
Delivering better patient outcomes takes the right economic instruments. Do market-access teams have the right tools at their disposal to make the value-for-money argument?
Long the only game in town, health insurers—many have observed—never mastered the art of customer service. But with a host of tech- and service-savvy upstarts making plays for "their" customers, the rules have changed. Sarah Mahoney examines how the new breed of insurers—who mix high tech with high touch—are trying to outflank the establishment
In theory, healthcare marketers love the idea of beacons. In practice? Well, nobody's sure whether patients and physicians will be wowed by their utility or turned off by their invasiveness. Barbara Peck offers a Beacons 101 primer
LabCorp's purchase of CRO Covance promises to open access to LabCorp's patient database for trial recruiting. Can this help resolve problems like the disparity of female representation and scarcity of subjects for studies?
Running clinical trials remains one of Big Pharma's biggest headaches. But thanks to canny use of social media, gamification techniques and even text messages, CROs have revitalized and revolutionized the process. Barbara Peck explains
The specter of a massive hack is haunting the healthcare industry. As it turns out, that might not necessarily be a bad thing for everyone involved. Sarah Mahoney explains
These 16 sprouts, from a field of 156, are looking up. With more nurturing, their buds could blossom. Marc Iskowitz reports
Buoyed by unprecedented success in hepatitis C, the biotech and pharma sectors had a strong 2014. And to hear ace Evercore ISI analyst Dr. Mark Schoenebaum tell it, everything's in place for growth in 2015 and beyond. Here, he takes both a look back and a look forward
For years, Congress has batted around the possibility of tax reform—and with it, the reduction or elimination of the tax deduction for marketing expenses. Could 2015 be the year that reform comes to pass? Larry Dobrow attempts to answer this and other pressing policy questions
Programmatic ad buying hasn't exactly taken over the industry, but its approach has precipitated a paradigm shift, media experts say.
Click the above link to access the complete Digital Edition of the December 2014 issue of MM&M, with all text, charts and pictures.
Dennis Urbaniak, managing director, Accenture Life Sciences
Click the above link to access the complete Digital Edition of the November 2014 issue of MM&M, with all text, charts and pictures.
Recent FDA draft guidance was meant to help companies create FDA-compliant tweets and handle third-party misinformation on the web. What other obstacles lie in the path of effective social media use?
A monthly showcase of companies offering expertise, experience and services within specific areas of the industry.
Striking the right tone in health communications with digital-savvy Millennials is tricky. Marc Iskowitz asks seven experts for some of the keys to facilitating that conversation
New therapies are shaking up MS and insomnia, while the slow pace of progress in Alzheimer's continues to frustrate patients and physicians alike. Welcome to neurology, where, Joe Dysart reports, treatment breakthroughs in certain areas are counteracted by setbacks in others
For all the talk about "the cloud," it promises most players in the pharma loop—sales and marketing execs, R&D teams and even the FDA—a better and faster way of doing business. Sarah Mahoney reports on how "the cloud" has become much more than a buzzword, and on what's inhibiting adoption
For the last few years, technology companies have been far more bullish about the potential of wearable health devices than healthcare organizations, never mind the consumers who were supposedly so eager to embrace them. New research, however, reveals that wearables may finally be catching on. Parks Associates' Harry Wang explains
As traditional saturation detailing and speaker programs lose ground, the advent of big data and analytics is letting pharma companies reach prized prescribers through new techniques like informed targeting and dynamic marketing. ZS Associates' Pratap Khedkar and Malcolm Sturgis explain
Hospitals used to be much more welcoming to pharma sales reps than they are today. Larry Dobrow looks at how the rise of the hospitalist has changed the game plan for getting the word out about products
Click the above link to access the complete Digital Edition of the October 2014 issue of MM&M, with all text, charts and pictures.
In an era when many patients prefer a conversation over a commercial, and as the FDA considers revisions to the "brief summary," how much risk information is necessary in DTC ads and why?
Hospira is taking to the courts to fight off generic threats to its hospital sedation drug Precedex
The anti-vaccination movement continues to make noise, but the Ebola scare has highlighted the role vaccines play in controlling diseases—and saving lives. Joe Dysart looks at the implications of the quest for an anti-Ebola vaccine, as well as the corporate shakeup in the vaccine sector.
As these eight pharma execs tell Larry Dobrow, achieving long-term success takes learning, listening, adapting and connecting with colleagues
Salaries are down,the industry gender gap persists and people have their eyes peeled for better gigs. But job satisfaction remains positive and, compared with other businesses, the pay isn't half-bad. James Chase attempts to make sense of the seeming contradictions
Steve Cashman, Founder and CEO, HealthSpot
Two FDA guidance documents on how health product manufacturers may participate in social media have each drawn criticism from affected industry and consumer groups.
What do healthcare agencies really want when it comes to potential employees? The answer to that question is in a constant state of flux, as technologies, clients' changing demands and the ever-expanding skill sets of a new generation of job seekers are transforming the rules of recruitment and hiring. Larry Dobrow reports
Click the above link to access the complete Digital Edition of the September 2014 issue of MM&M, with all text, charts and pictures.
GSK's decision to cut Advair's price spurred some PBMs to put it back on formulary. Will drugmaker discounts diminish the need for loyalty programs? How can these programs stay relevant beyond giving co-pay assistance?
To see what's new in the women's health market, it might be necessary to take a look back. The return of the IUD is just one comeback shaping the future of a field that has never been a stranger to controversy. Noah Pines reports on the latest developments in this space
Welcome to patient education circa 2014: With patient expectations at an all-time high, pharma marketers are struggling to keep up in the quest to make meaningful contact with tech-empowered audiences. But a few savvy companies seem to have cracked the communication code, moving to the forefront of this movement. Larry Dobrow reports
Print's numbers may be taking some small steps in the right direction, but data is what the industry really wants to sink its teeth into. Larry Dobrow reports on what 2014's slight uptick means in the context of an evolving media mix
Andrew Thompson, CEO, Proteus Digital Health
As its focus moves from manufacturing to service, pharma needs to partner with healthcare neophytes as well as established players. James Chase asks six experts to assess the risks and opportunities
FDA's current re-examination of its off-label promotion policies in light of the First Amendment is a delicate balancing act between its rock-solid traditional enforcement posture and a diverse new electronic communications environment.
Click the above link to access the complete Digital Edition of the August 2014 issue of MM&M, with all text, charts and pictures.
Stuart Raetzman, CEO, Galderma Labs
Pharma cites "payer pressure" as one of its biggest marketing challenges yet struggles to make the "value" case for products. How can it translate market-access awareness into reimbursement success?
More than 100 esteemed industry leaders and thinkers spent several hours discussing, reviewing and scoring around 700 entries to the MM&M Awards. Here are the results of their efforts—the 2014 finalists
Pharma is moving toward a broader treatment paradigm based on providing additional services for patients. Boris Kushkuley describes what the Pill+ model looks like, and how multichannel marketing can facilitate it
Immunotherapy is an emerging powerhouse in cancer treatment. Early gains being made in multiple tumor types provide a glimpse of the effectiveness of several agents and regimens. While longer follow-up is needed, the results have analysts talking about a big shift in the war on cancer. Joe Dysart reports
When assessing the value of breakthrough drugs, Health Economics & Outcomes Research can help generate the economic profile of a new therapy. Mohan Bala and Meghan Gallagher explain its use
A major information explosion is just the tip of the iceberg in the paradigm shift that is taking place between pharma, marketers and the patients that they serve. James Chase asks experts from across the patient-to-pharma spectrum how the industry can negotiate the new environment to successfully put patients first
Innovation is still valued in the orphan-drug space, but the reimbursement bar is rising. NPS Pharma's Eric Pauwels, who's launched five ultra-rare disease products, explains how these biotech brands can demonstrate their value. Marc Iskowitz reports
Last week, the former FDA branch chief who originally approved LASIK machines asked FDA to reconsider its denial last month of his petition to ban these devices.
Recent treatments in CF, including the inhaled antibiotic Tobramycin, have increased lifespan well into adulthood.
Click the above link to access MM&M's first Leadership Exchange Uncut e-book, "The Agency-Client Relationship"
A steady focus on data analytics brings a new level of relevance
At Chicago firm, new business and a new strategic partnership
Thinking globally leads this agency to continued solid performance
Bucking the "monolithic" model results in client, revenue growth
After 30 years in the business, still finding new avenues to explore
Chicago firm broadens its base beyond a rare-disease specialty
A focus on specialty pharma puts this agency in a solid position
Longtime "patient-centric" agency sets the engagement standard
Getting out of the "professional agency box" spurs major growth
Launch leaders: Agency excels at helping brands get to market
Changing technology opens a path to "business transformation"
Chicago firm leverages specialty expertise into growing revenues
Getting out of its comfort zone lets agency pursue new opportunities
New collaboration at the top invigorates inVentiv Health shop
Keeping an eye on the media mix while never losing sight of digital
An agency with a big name and clients takes a personal approach
Agency comes out swinging after Pfizer hit, and scores a comeback
A broader scope opens the path to a new set of opportunities
Tempering a diversification drive with a focus on the fundamentals
Understanding patient behavior helps this agency bring in clients
A nimble, flexible approach attracts a diversified client base
Change is a constant across the board for this Boston-based firm
Launches and orphan brands lead agency to its "best year ever"
Even a year filled with changes "didn't change who we were"
"Great growth, new clients, new work" at this McCann shop
A new leader aims to transform both his agency—and healthcare
Maintaining a culture that has brought about long-term success
Taking a different line of thought brings double-digit growth
A well-planned transition puts agency in "a place of strength"
Using a "full-circle" approach attracts a broad range of clients
Future-focused, "fiercely independent" Toronto agency continues to surge
Moving past the consolidation hurdle with expansion and strength
Solid knowledge of devices and diagnostics brings in business
Achieving success by creating unique experiences, not just ads
A hi-tech focus adds devices work to Toronto shop's roster
A David that can go toe-to-toe with the network-agency Goliaths
This compelling e-book shares a wealth of insights designed to help members of sales forces connect with elusive HCPs. An expanded version has also been created that includes video interviews and other multimedia content. Click here for access.